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Available online 30 October 2016Background: The performance of the GRACE, HEART and TIMI scores were compared in predicting the probability
of major adverse cardiac events (MACE) in chest pain patients presenting at the emergency department (ED), in
particular their ability to identify patients at low risk.
Methods: Chest pain patients presenting at the ED in nine Dutch hospitals were included. The primary outcome
wasMACEwithin 6weeks. The HEART score was determined by the treating physician at the ED. The GRACE and
TIMI score were calculated based on prospectively collected data. Performance of the scores was compared by
calculating AUC curves. Additionally, the number of low-risk patients identiﬁed by each score were compared
at a ﬁxed level of safety of at least 95% or 98% sensitivity.
Results: In total, 1748 patients were included. The AUC of GRACE, HEART, and TIMI were 0.73 (95% CI: 0.70–
0.76%), 0.86 (95% CI: 0.84–0.88%) and 0.80 (95% CI: 0.78–0.83%), respectively (all differences in AUC highly
statistically signiﬁcant). At an absolute level of safety of at least 98% sensitivity, the GRACE score identiﬁed
231 patients as “low risk” in which 2.2% a MACE was missed; the HEART score identiﬁed 381 patients as
“low risk” with 0.8% missed MACE. The TIMI score identiﬁed no “low risk” patients at this safety level.
Conclusions: The HEART score outperformed the GRACE and TIMI scores in discriminating between those
with and without MACE in chest pain patients, and identiﬁed the largest group of low-risk patients at the
same level of safety.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Acute coronary syndrome1. Background
Up to 6.3% of emergency department (ED) visits are related to chest
pain [1]. An urgent question in these patients is whether they have an
acute coronary syndrome (ACS), as any delay in diagnosis and treat-
ment can have a negative impact on their prognosis [2–4]. Normal
values of troponin and a normal electrocardiogram (ECG) still do not
exclude ACS completely. As a result, many patients presenting withh Sciences and Primary care,
AB Utrecht, The Netherlands.
dervaart).
eliability and freedom from bias
land Ltd. This is an open access articlchest pain are currently hospitalized and extensively evaluated with
non-invasive stress testing or imaging, or with an invasive coronary an-
giography [5]. However, of all chest pain patients b25%will have anACS
[5]. If patients at low risk for ACS could be recognized early in the
diagnostic process, it has the potential to reduce patient burden, length
of stay at the ED, frequency of hospitalization and costs [6–8].
To diagnose ACS, physicians use patient history, ECG abnormalities,
cardiac markers (notably troponin) and several other potential vari-
ables [2,9]. International cardiac guidelines state that chest pain patients
presenting to the ED should be assessed with a risk stratiﬁcation tool or
risk score [2,10,11] and over the years, a number of tools have been de-
veloped [12–20]. Threewell-known risk scores are theGRACE score, the
HEART score and the TIMI score, see Table 1 and Supplementary mate-
rial A.1 [15,16,19]. Risk scores combine and weigh various predictors toe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Variables present in GRACE score, HEART score and TIMI score.
Variables GRACE score HEART score TIMI score
Age X X X
Gender
History Suspicious (physicians' opinion) X
Severe angina (≥2 events in last 24 h) X
Use of aspirin last 7 days X
Killip class X
Physical examination Heart rate X
Systolic blood pressure X
ECG ST deviation X X X
Repolarization disorder, LBBB or pacemaker X
Cardiac arrest at admission X
Laboratory results Creatinin level X
Positive cardiac enzyme⁎ X X X
Risk factors Previous atherosclerotic disease† X
Previous coronary artery disease ≥50% X
Current smoking‡ X X
Diabetes mellitus X X
Family history of cardiovascular disease X X
Hypercholesterolemia X X
Hypertension X X
Obesity (body mass index N30) X
ECG: electrocardiogram, LBBB: left bundle branch block.
⁎ Troponin or creatin kinase–MB.
† Previous atherosclerotic disease was deﬁned as myocardial infarction, coronary arterial bypass grafting, percutaneous coronary intervention, stroke or transient ischemic attack, pe-
ripheral artery disease.
‡ Smoking in the HEART –impact trial was deﬁned as smoking currently or stopped b3 months.
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readily available information collected during the initial work-up of
chest pain patients.
Studies directly comparing the performance of risk scores in the
same population of chest pain patients report conﬂicting results in
terms of which score is preferred to use at the ED [21–24]. Furthermore,
it is unclear which risk score performs best in identifying patients at
“low risk” of ACS, as these patients are candidates for early discharge
from the ED (triage role). Therefore, we compared the performance of
the GRACE, HEART and TIMI risk scores in identifying best patients at
“low risk” of ACS in patients presenting with chest pain at the ED.
2. Methods
2.1. Design and study population
Our study population consisted of patients participating in the
HEART-impact trial. In short, this trial investigated the impact of the
use of the HEART score in daily practice on safety, quality of life and
use of health care resources. The trial was designed as a pragmatic,
stepped wedge, cluster randomized trial and compared usual care
with HEART score care (i.e. calculation of the HEART score and adher-
ence to recommended patient management depending on the score;
see Fig. A.1 and [25]). In this stepped wedge design all hospitals (clus-
ters) startedwith an initial period of usual care. Subsequently, at regular
intervals (“steps”), each hospital switched to using the HEART score. At
the end of the trial all hospitals had crossed over to using the HEART
score. The order in which hospitals switched was randomized. A total
of 9 hospitals in the Netherlands participated. Any patient with chest
pain presenting to the ED was eligible for inclusion. Patients directly
recognized as having ST-elevation myocardial infarction (STEMI) were
excluded, because of the lack of diagnostic uncertainty. All included pa-
tients provided written informed consent. The studywas conducted ac-
cording to the principles of the current version of the declaration of
Helsinki and in accordance with the Dutch law onMedical Research In-
volving Human Subjects Act (WMO). The trial was approved by the In-
stitutional Review Board of the University Medical Center Utrecht, the
Netherlands, and subsequently by the Boards of the participating hospi-
tals. Characteristics of the used troponin assays are shown in Table A.1.Further details can be read in the published study protocol [25]. For our
current study, we only analysed patients whowere included during the
HEART care period (half of the total HEART-Impact trial population),
since speciﬁc measures were taken during the usual care period of the
HEART-Impact trial to ensure the HEART score was not calculated.
2.2. Endpoints
The main endpoint in our study was major adverse cardiac events
(MACE) within 6 weeks after the initial ED presentation (including
the index event). MACE consisted of unstable angina (UA), non-ST ele-
vation myocardial infarction (NSTEMI), STEMI, percutaneous coronary
intervention (PCI), coronary arterial bypass grafting (CABG), stenosis
managed conservatively, cardiovascular death, non-cardiovascular
death and death with unknown cause. The potential occurrence of
MACE was identiﬁed by means of a phone call with each patient at
3 months after presentation [25]. In all cases the patient could not be
contacted, the patient's general practitioner was contacted. In all pa-
tients with a possible MACE or unknown status, the electronic hospital
records were investigated. All information possibly indicating MACE
was further investigated by examiningmedical records from the hospi-
tal and/or the general practitioner. All potential events were then adju-
dicated by two independent cardiologists and it was decidedwhether a
MACE occurred or not. The adjudication was done blinded for the
GRACE, HEART and TIMI scores [25].
2.3. Calculation of the risk scores and their performance
All variables used in the risk scores were collected at time of presen-
tation at the ED and are depicted in Table 1. The GRACE score and TIMI
score were calculated automatically from the prospectively collected
data, without interpretation by the investigators. The HEART score
was calculated by physicians at themoment of admission at the ED dur-
ing the HEART care period [25]. One of the key roles of these risk scores
is to identify patients at low risk for MACE. Therefore, we compared the
number of patients identiﬁed as “low risk” at a ﬁxed level of safety. In
scenario 1, we calculated the cut-off for each risk score with an absolute
safety level of no N5% of all patientswithMACE beingmissed, i.e. at least
95% sensitivity. The risk score with the highest number of patients
Fig. 1. Patientﬂowchart for patients included in current comparison of performance of the
GRACE score, HEART score and TIMI score.
Table 2
Baseline characteristics.
All patients (n = 1748)
Demographics
Male 937 (54%)
Mean age (SD) 62 (14)
Vital signs at presentation
Mean systolic blood pressure in mm Hg (SD) 144 (23)
Mean diastolic blood pressure in mm Hg (SD) 81 (13)
Mean heart frequency per minute (SD) 73 (15)
Killip class I 1723 (99%)
Cardiac risk factors
Diabetes Mellitus 271 (16%)
Obesity (BMI N30 kg/m2) 319 (18%)
Hypercholesterolemia 559 (32%)
Hypertension 846 (48%)
Positive family history 629 (36%)
Current smoking 441 (25%)
History of cardiovascular disease 576 (33%)
History of AMI 277 (16%)
History of PCI 331 (19%)
History of CABG 128 (7%)
History of CVA/TIA 98 (6%)
History of peripheral artery disease 69 (4%)
Laboratory results at presentation
Mean creatinin in μmol/l (SD) 80 (33)
Medication at presentation
Aspirin 597 (34%)
P2Y12-inhibitor (clopidogrel) 107 (6%)
Vitamin K antagonists (coumarin) 162 (9%)
Other (Dipyridamol, Ticagrelor, DOAC) 62 (4%)
SD: standard deviation,mmHg:millimetres ofmercury, BMI: BodyMass Index, AMI: acutemyo
grafting, CVA: cerebrovascular attack, TIA: transient ischemic attack, DOAC: direct oral anticoa
658 J.M. Poldervaart et al. / International Journal of Cardiology 227 (2017) 656–661identiﬁed as low risk considering this safety level can then be consid-
ered themost efﬁcient score.We also considered scenario 2,with an ab-
solute safety level of missing not N2% of all patients with MACE, i.e. at
least 98% sensitivity. Both scenarios of safety levels were based on the
ﬁrst measurement of troponin at the ED. To reﬂect current clinical prac-
tice most closely, we also calculated all three scores based on the ﬁrst
and (when available) second troponinmeasurement and again assessed
the scores' efﬁciency and safety. Furthermore, to facilitate comparison
with other studies, we also assessed the efﬁciency and safety, when
the primary endpoint of MACE consisted of only acute myocardial in-
farction (AMI) and/or death.
2.4. Statistical analysis
Continuous variables were presented as means with standard devi-
ations, categorical variables were presented as absolute number of pa-
tients with corresponding percentages. Cut-off values of troponin
were provided by all participating hospitals to assess whether the
level of this cardiac marker was elevated.We compared the discrimina-
tion of the three scores by examining their ROC curves and calculating
the areas under the ROC curve (AUCs), also known as the c-statistic,
and the corresponding 95% conﬁdence intervals (CI). To compare the
c-statistics we used the method of DeLong [26], which takes into ac-
count the paired nature of our data as all three scores were determined
in each patient. Because of the within-patient comparison of scores, the
effect of clusteringwithin hospital was not taken into account. We used
Statistical Package for the Social Sciences (IBM SPSS statistics, version
21) for all statistical analyses, except for the comparison of the paired
ROC curves and AUC for which we used SAS version 9.1.
3. Results
3.1. Study population
Patients were enrolled between July 1, 2013 and August 31, 2014 in
nine hospitals in the Netherlands. For patient ﬂow see Fig. 1. In totalPatients with MACE (n = 326) Patients without MACE (n = 1422)
227 (70%) 710 (50%)
67 (11) 60 (15)
147 (23) 143 (23)
82 (13) 81 (13)
75 (17) 73 (15)
317 (97%) 1406 (99%)
68 (21%) 203 (14%)
58 (18%) 261 (18%)
117 (36%) 442 (31%)
209 (64%) 637 (48%)
117 (36%) 512 (36%)
81 (25%) 360 (25%)
154 (47%) 422 (30%)
65 (20%) 212 (15%)
91 (28%) 240 (17%)
36 (11%) 92 (6%)
27 (8%) 71 (5%)
25 (8%) 44 (3%)
85 (22) 78 (35)
153 (47%) 444 (31%)
40 (12%) 67 (5%)
33 (10%) 129 (9%)
14 (4%) 48 (3%)
cardial infarction, PCI: percutaneous coronary intervention, CABG: coronary arterial bypass
gulant.
Fig. 2. Receiver-operating-characteristic (ROC) curves and corresponding Areas under the
curve (AUCs) of the GRACE, HEART and TIMI score to predictmajor adverse cardiac events
within 6 weeks.
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(50%) patients included during HEART care period. Of these 1833
HEART care patients, 10 patients (0.5%) were lost to follow-up, and 2
patients (0.1%) withdrew their informed consent. In a total of 73
(4.0%) patients, one or more risk score could not be calculated and
therefore 1748 patients were used in the analysis. The mean age of
these patients was 62 years and 54% were male. Patient characteristics
are shown in Table 2.
3.2. Endpoints
A total of 542 MACE occurred in 325 (19%) patients, consisting of 99
UA, 201 NSTEMI, 11 STEMI, 41 stenosis managed conservatively, 140
PCI, 45 CABG, one cardiovascular death, one non-cardiovascular death
and three deaths from an unknown cause.
3.3. Performance of the risk scores
In Fig. 2, the ROC curves of the GRACE score, HEART score and TIMI
score to predict major adverse cardiac events within 6 weeks areTable 3
Comparison of performance of GRACE score, HEART score and TIMI score in terms of safety an
Scenario 1: at least 95% sensitivity GRAC
Corresponding cut-off for “low risk” ≤72 p
Number of patients classiﬁed “low risk” / total number of patients 334/1
Percentage of MACE in “low risk” group 3.6% (
MACE, of which AMI 5
MACE, of which death 0
Negative predictive value (NPV) 96% (
Scenario 2: at least 98% sensitivity GR
Corresponding cut-off for “low risk” ≤6
Number of patients classiﬁed “low risk” / total number of patients 231
Percentage of MACE in “low risk” group 2.2
MACE, of which AMI 1
MACE, of which death 0
Negative predictive value (NPV) 98%
MACE: major adverse cardiac events, AMI: acute myocardial infarction.
⁎ At the lowest TIMI score, this absolute safety level is not reached unless all patients are clashown. The AUC of the HEART score was highest with 0.86 (95% CI:
0.84–0.88), followed by the AUC of the TIMI score with 0.80 (95%
CI: 0.78–0.83) and the GRACE score with an AUC of 0.73 (95% CI:
0.70–0.76). All differences in AUC were highly statistically signiﬁcant:
all p-values b0.001.
Table 3 shows the comparison of performance of GRACE, HEART and
TIMI score in terms of safety and efﬁciency. Scenario 1 used an absolute
level of safety of missing no N5% of all patients with MACE to deﬁne a
“low-risk” group. At this absolute safety level, theGRACE score classiﬁed
334 patients as “low risk” of whom 12/334 (3.6%) patients developed
MACE. Using the same absolute safety level, the HEART score classiﬁed
708 patients as “low risk” with 14/708 (2.0%) patients developing
MACE. Lastly, the TIMI score identiﬁed 439 patients as “low risk” with
14/439 (3.2%) having a MACE.
We repeated the analyses at a different absolute safety level of
missing no N2% of MACE in all patients with MACE (scenario 2). This
sensitivity analysis showed that theHEART score againwas themore ef-
ﬁcient scorewith a low-risk group of 381 patients versus 231 andnopa-
tients for the GRACE and TIMI scores, respectively. The proportion of
MACE in these low-risk groups were 0.8% and 2.2% for respectively the
HEART and GRACE scores. Furthermore, to facilitate comparison with
other studies, we also identiﬁed the number of patients with an AMI
or death, which are shown in Table 3.
In current practice, serial measurements of troponin are being used.
To reﬂect this we performed an additional analysis in which the scores
were based on the ﬁrst and second troponin measurement. A second
troponin measurement was performed in 955 of the 1748 patients
(55%). Addition of the second troponin (when performed) in the calcu-
lation of the risk scores did not show different results, as depicted in
Table 4.
4. Discussion
Our head-to-head comparison of three well-known and extensively
validated risk scores in 1748 patients presenting with chest pain at the
ED, showed that at a same level of safety not missing N5% of all patients
with ACS, the number of low-risk patients identiﬁed by theHEART score
was higher than by the GRACE or TIMI scores. At a maximum of 2%
missed cases, results were similar. Furthermore, the HEART score had
the highest overall discrimination to predict MACE with an area under
the ROC curve of 0.86 (95% CI: 0.84–0.88), followed by the TIMI score
with an AUC of 0.80 (95% CI: 0.78–0.83) and the GRACE score (0.73,
95% CI: 0.70–0.76).
In the literature, mostly comparable results were found when com-
paring the HEART and TIMI scores. In one study, the AUC of the HEART
score was 0.83 (95% CI: 0.81–0.85) and the AUC of the TIMI score
(0.75, 95% CI: 0.72–0.77) was slightly lower than the AUC of 0.80 wed efﬁciency.
E score HEART score TIMI score
oints ≤3 points 0 points
748 (19.1%) 708/1748 (40.5%) 439/1748 (25.1%)
12/334) 2.0% (14/708) 3.2% (14/439)
3 0
1 0
94%–98%) 98% (97–99%) 97% (95–98%)
ACE score HEART score TIMI score
6 points ≤2 points –⁎
/1748 (13.2%) 381/1748 (21.8%) –
% (5/231) 0.8% (3/381) –
1 –
0 –
(95–99%) 99% (98–100%) –
ssiﬁed as high risk.
Table 4
Comparison of performance of GRACE score, HEART score and TIMI score in terms of safety and efﬁciency, based on the ﬁrst and second troponin measurement (performed in N= 955).
Scenario 1: at least 95% sensitivity GRACE score HEART score TIMI score
Corresponding cut-off for “low risk” ≤73 points ≤3 points 0 points
Number of patients classiﬁed as “low risk” / total number of patients 340/1748 (19.5%) 707/1748 (40.5%) 430/1748 (24.6%)
Percentage of MACE in “low risk” group 4.1% (14/340) 1.8% (13/707) 1.9% (8/430)
Of which AMI 5 3 0
Of which death 0 1 0
Negative predictive value (NPV) 96% (93–98%) 98% (97–99%) 98% (96–99%)
Scenario 2: at least 98% sensitivity GRACE score HEART score TIMI score
Corresponding cut-off for “low risk” ≤67 points ≤2 points –⁎
Number of patients classiﬁed as “low risk” / total number of patients 243/1748 (13.9%) 381/1748 (21.8%) –
Percentage of MACE in “low risk” group 2.5% (6/243) 0.8% (3/381) –
Of which AMI 1 1 –
Of which death 0 0 –
Negative predictive value (NPV) 97% (95–99%) 99% (98–100%) –
MACE: major adverse cardiac events, AMI: acute myocardial infarction.
⁎ At the lowest TIMI score, this absolute safety level is not reached unless all patients are classiﬁed as high risk.
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TIMI risk scores, the TIMI score AUCwas 0.79 (95% CI: 0.74–0.83), a sim-
ilar result we found in our analysis. The AUC for the GRACE score was
considerably higher, namely 0.83 (95% CI: 0.79–0.87), whichmay possi-
bly be explained by the smaller deﬁnition ofMACE and shorter duration
of follow-up [23]. On the other hand, Carlton et al. showed that TIMI
would be the more effective risk score, but neither HEART nor TIMI
reached a 1% miss-rate for AMI with addition of either high-sensitive
troponin [20]. Additionally, in this study only AMI was included as an
outcome measure, instead of the broad endpoint deﬁnition we used
[27].
One valuable role for cardiac risk scores is to identify patients as low-
risk in order to avoid further testing and hospital admission in these pa-
tients (triage role). An ideal triage instrumentwould identify the largest
number of patients at low risk (i.e. efﬁciency) without compromising
safety,meaning that the number of patients classiﬁed as low risk but de-
velopingMACE (i.e. false negatives) should be low.When setting an ab-
solute safety level for missed MACE of 5% of total patients, the HEART
score identiﬁes the most patients as “low risk”, namely 708 patients,
with 14 patientsmissed of the total 325 patients withMACE. This corre-
sponds to a proportion of MACE in the low-risk group of 2.0%. Although
the deﬁnition of an acceptable false-negative rate is susceptible to per-
sonal opinions, and may vary between countries, Than et al. and Kline
et al. estimate that the most clinicians would accept a false-negative
rate of 1 to 2% [28,29]. When repeating the analyses at a different abso-
lute safety level of missing no N2% of all patients withMACE, the HEART
score was again the most efﬁcient score with 381 patients identiﬁed as
low risk, resulting in a cumulative incidence of MACE in this low-risk
group of 0.8%, which is below the mentioned more conservative 1%
false-negative rate.
The better performance of the HEART score compared to the TIMI
and GRACE scores may be explained by the differences in the patient
populations in which the three risk scores were developed. The
HEART score was speciﬁcally developed for unselected patients with
chest pain presenting at the ED, thus, a clinical domain characterized
by diagnostic uncertainty [15]. The GRACE score was developed in pa-
tients already diagnosed with ACS [30,31], thus with a higher risk of
AMI and/or death than an unselected population with chest pain at
the ED. Similarly, the TIMI scorewas developed in a group of patients al-
ready diagnosed with UA or NSTEMI [19]. Importantly, our HEART-
impact trial cohort consisted only of patients in whom a diagnostic di-
lemma persisted and patients with STEMI were excluded. The GRACE
and TIMI scores are well-known scores and are supported by current
clinical guidelines [2,4,10,11], but seem more suitable as a (short-
term) prognostic score in patients already diagnosed with ACS. A
strength of the GRACE score is that it was derived in a large dataset of
11,389 patients [30,31]. The range of the outcome of the GRACE scoreis very wide (1 to 372), therefore small differences in patient character-
istics will result in a speciﬁc score for every patient. However, the large
range of total score outcomeswith the GRACE score demands the use of
a computer, making it more difﬁcult to apply at the bedside, although
smartphone apps might diminish this issue. The HEART and TIMI
score have a smaller range of total scores from 0 to 10 and 0–7 respec-
tively. The HEART scores' strength is that all ﬁve variables included in
the score are derived from clinical practicewhichmakes it simple to cal-
culate the score at the bedside, improving applicability for physicians.
Interestingly, the HEART score was not developed using mathematical
modelling from real-life data, but developed by a cardiologist based on
clinical experience and later on validated in clinical databases [15]. A
limitation of the HEART score is the subjectivity of the ﬁrst element,
(i.e. whether history taking indicates ACS), although it is widely accept-
ed that this is a clinically relevant element. Furthermore, the score uses
a cut-off of 1.7% as being “low risk”, which can arguably be too high in
some countries [28,29]. However, the aim of this studywas not to deter-
mine an optimal cut-off for the risk scores, as this is subject to debate.
The TIMI score has as strength that it is comprised of statistically signif-
icant predictors, is derived in a large dataset of 1957 patients and con-
sists of only seven clinical elements that can be calculated at the
bedside. However, as shown, the TIMI score only identiﬁes a small pro-
portion of patients as “low risk” who are eligible for early discharge,
making it not the most efﬁcient score for triage.
4.1. Study limitations
A number of limitations of our study should be mentioned. Firstly,
we chose to validate the GRACE, HEART and TIMI scores, while currently
several other risk scores are available [12,14,17,18]. We consulted sev-
eral experienced cardiologists, who found that most currently available
risk scores were not used in daily practice, or that the scores included
variables not routinely assessed by clinicians. Secondly, the GRACE
score and TIMI score were calculated from prospectively collected vari-
ables, blinded for the primary endpoints. These variables were deﬁned
before the start of the trial and included in our data collection form at
the ED. Cliniciansmight take other variables into accountwhen calculat-
ing a risk score in daily practice; although the GRACE and TIMI score
consist of more objective variables than the HEART score, we cannot
rule out that in our study the performance of theGRACE and TIMI scores
could have been underestimated to some extent. Lastly, we did not in-
clude serial troponin measurements in our study, while this is current
policy in most hospitals. However, we did perform additional analyses
based on available second troponin measurements into the calculation
of all three risk scores, with the aim tomore closely reﬂect current clin-
ical practice. It should be noted physicians did not perform second tro-
ponin measurements in all patients, but only in the patients of whom
661J.M. Poldervaart et al. / International Journal of Cardiology 227 (2017) 656–661they deemed this was necessary. Also in these additional analyses, the
HEART score had the highest discriminative power.
5. Conclusions
From our head-to-head comparison of the GRACE, HEART and TIMI
score in a large prospective cohort of chest pain patients presenting to
the ED, we conclude that the HEART score performed best in discrimi-
nating between those with andwithoutMACE. The HEART score identi-
ﬁed the largest number of patients (40.5%) as low risk without
compromising safety. We recommend the use of the HEART score in
the work-up of patients with chest pain at the ED.
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